$SCTX

Scribe Therapeutics (SCTX) presented data at AHA 2026 showing its gene therapy STX-1150 maintained LDL cholesterol control for two years in non-human primates. The therapy uses epigenetic gene silencing to target PCSK9. Separately, Scribe's STX-1200, a CRISPR-based LPA gene editor, showed durable Lp(a) reduction in preclinical models. Novartis' pelacarsen failed to reduce cardiovascular events in a Phase 3 trial, impacting competitors.

Cathie Wood's Ark Invest sold shares of Palantir (PLTR), Alphabet (GOOG), Shopify (SHOP), and others, while adding positions in biotech firms like Pacific Biosciences (PACB), Scribe Therapeutics (SCTX), and Freenome (FRNM). The trades occurred across several ARK ETFs, including ARK Innovation and ARK Genomic Revolution.

ARK ETFs sold 17,053 shares of Shopify (SHOP) and bought 199,698 shares of Scribe Therapeutics (SCTX) on October 21st, 2026. Other notable trades included selling Personalize (PSNL) and buying Intuitive Surgical (ISRG) and X-Energy (XE).

Cathie Wood's Ark Invest purchased shares of CoreWeave (CRWV), Scribe Therapeutics (SCTX), and Freenome (FRNM), all trading 28% to 57% below their highs. CoreWeave saw 113% revenue growth but remains unprofitable. Scribe Therapeutics focuses on gene silencing and has cash until 2029. Freenome gained FDA approvals for cancer screening tests and rose 7% post-purchase.

ARK ETFs sold 670,746 shares of Personalised (PSNL) for $10.7M, bought 254,668 shares of Freenome (FRNM) for $3.1M, sold 59,477 shares of CareDx (CDNA) for $4M, and bought 29,416 shares of Scribe Therapeutics (SCTX) for $609K. These trades indicate ARK's strategic portfolio adjustments.

ARK ETFs sold 16,422 Alphabet (GOOGL) shares for $5.8M, bought 359,612 Rocket Lab (RKLB) shares for $25.1M. Also reduced Twist Bioscience (TWST) and 10X Genomics (TXG) positions, while increasing stakes in Scribe Therapeutics (SCTX), Veracyte (VCYT), and Beam Therapeutics (BEAM).

ARK Genomic Revolution ETF (ARKG) managed by Cathie Wood bought shares of Ionis Pharmaceuticals (IONS), Veracyte (VCYT), Beam Therapeutics (BEAM), and Scribe Therapeutics (SCTX), while selling 10x Genomics (TXG). Other ETFs like GNOM, PBE, FBT, and XBI also hold these biotech companies, offering varied exposure to genomics and biotechnology sectors.

ARK Invest increased stakes in Ionis Pharmaceuticals (IONS), Veracyte (VCYT), Scribe Therapeutics (SCTX), and Beam Therapeutics (BEAM), while reducing exposure to 10x Genomics (TXG). The ETF bought shares worth millions in each biotech firm, with IONS, SCTX, and BEAM seeing pre-market gains, while VCYT declined. ARK also invested $37 million in Meta Platforms (META) across three ETFs, following a surge in Meta's shares.

Scribe Therapeutics, Inc. (SCTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to d

Analysts upgraded Deere (DE) to Outperform with a $800 target, citing strong North American demand. Abercrombie & Fitch (ANF) was upgraded to Buy with a $162 target after Q2 earnings beat. Agco (AGCO) upgraded to Outperform with a $150 target, expecting 2027 volume recovery. Kaiser Aluminum (KALU) upgraded to Buy with a $184 target. Stag Industrial (STAG) upgraded to Outperform. PG&E (PCG) downgraded by Wells Fargo and BMO. Mizuho downgraded PG&E, Sempra Energy (SRE), and Edison International (E